Programmed death-1/ligand 1 (PD-1/PDL-1) inhibitors and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitors have shown significant potential in improving overall survival (OS) in patients with malignant melanoma, non-small cell lung carcinoma, renal cell carcinoma, and other tumors [1]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.